MS and Demyelinating Disorders

Here's some of what is coming soon to NeurologyLive® this week.

The trial evaluates safety, remyelination, and functional outcomes, including changes in low contrast letter acuity, MRI myelination measures, and MS disease activity.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

A large registry-based study analyzed treatment patterns and attack risks in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

A unique case highlighted the complex interplay between NMOSD and other autoimmune diseases, demonstrating the challenges in diagnosing and managing the condition.

Neal K. Shah talked about an artificial intelligence innovation that can be used to fight denied health insurance claims, thus improving revenue cycle management for physicians' practices and the patient experience.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 31, 2024.

Kiranpal Singh Sangha, PharmD, clinical pharmacy specialist and adjunct assistant professor of pharmacy at The University of Cincinnati, talked about the vital role of clinical pharmacists in neurology, specifically in multiple sclerosis care.

Treatment with foralumab, an anti-CD3 monoclonal antibody, led to the discovery of several biomarkers known to be associated with antigen presentation, interferon responses, and other regulatory immune mechanisms.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 24, 2024.

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

The PoNSTEP study demonstrated significant gait improvement with PoNS Therapy, showing a mean DGI increase of 5.0 at week 14, adherence-related gains during Phase 2, and sustained benefits for most participants six months post-treatment.

The professor of neurology at University of Florence talked about how early intervention, broader assessment tools, and personalized approaches are essential for effectively managing multiple sclerosis. [WATCH TIME: 4 minutes]

A 51-year-old patient with neuromyelitis optica spectrum disorder and hemorrhagic longitudinally extensive transverse myelitis presented a challenging case.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed how a recently published preclinical study adds to the understanding of neuropilin-1 in chronic pain. [WATCH TIME: 3 minutes]

These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

At ECTRIMS 2024, the consultant neurologist at Queen's Square MS Center in London talked about the evolving McDonald criteria to define multiple sclerosis biologically. [WATCH TIME: 5 minutes]

A new study suggests particulate matter exposure exacerbated the severity of multiple sclerosis and neuromyelitis optica spectrum disorder, with significant clinical and radiological impacts.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 17, 2024.

At ECTRIMS 2024, the postdoctoral researcher at Amsterdam University Medical Center talked about an evolving tool developed to predict disease progression in multiple sclerosis. [WATCH TIME: 7 minutes]